DVA Quote, Financials, Valuation and Earnings

Quest Diagnostics, Inc. has a net margin of 8.45% compared to DaVita, Inc.'s net margin of 9.12%. DaVita, Inc.'s return on equity of 67.52% beat Quest Diagnostics, Inc.'s return on equity of 14.49%.

DaVita, Inc. has a consensus price target of $151.71, signalling downside risk potential of -0.54%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $217.38 which suggests that it could grow by 2.97%. Given that Quest Diagnostics, Inc. has higher upside potential than DaVita, Inc., analysts believe Quest Diagnostics, Inc. is more attractive than DaVita, Inc..

DaVita, Inc. has a beta of 0.994, which suggesting that the stock is 0.558% less volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.785%.

DaVita, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.52% to investors and pays a quarterly dividend of $0.80 per share. DaVita, Inc. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 36.57% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita, Inc. quarterly revenues are $3.6B, which are larger than Quest Diagnostics, Inc. quarterly revenues of $2.8B. DaVita, Inc.'s net income of $306M is higher than Quest Diagnostics, Inc.'s net income of $256M. Notably, DaVita, Inc.'s price-to-earnings ratio is 15.96x while Quest Diagnostics, Inc.'s PE ratio is 24.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita, Inc. is 0.85x versus 2.16x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Encompass Health Corp. has a net margin of 8.45% compared to DaVita, Inc.'s net margin of 13.1%. DaVita, Inc.'s return on equity of 67.52% beat Encompass Health Corp.'s return on equity of 24.74%.

DaVita, Inc. has a consensus price target of $151.71, signalling downside risk potential of -0.54%. On the other hand Encompass Health Corp. has an analysts' consensus of $142.73 which suggests that it could grow by 33.14%. Given that Encompass Health Corp. has higher upside potential than DaVita, Inc., analysts believe Encompass Health Corp. is more attractive than DaVita, Inc..

DaVita, Inc. has a beta of 0.994, which suggesting that the stock is 0.558% less volatile than S&P 500. In comparison Encompass Health Corp. has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.06%.

DaVita, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health Corp. offers a yield of 0.67% to investors and pays a quarterly dividend of $0.19 per share. DaVita, Inc. pays -- of its earnings as a dividend. Encompass Health Corp. pays out 13% of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita, Inc. quarterly revenues are $3.6B, which are larger than Encompass Health Corp. quarterly revenues of $1.5B. DaVita, Inc.'s net income of $306M is higher than Encompass Health Corp.'s net income of $202.3M. Notably, DaVita, Inc.'s price-to-earnings ratio is 15.96x while Encompass Health Corp.'s PE ratio is 19.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita, Inc. is 0.85x versus 1.85x for Encompass Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Healthcare Services Group, Inc. has a net margin of 8.45% compared to DaVita, Inc.'s net margin of 6.7%. DaVita, Inc.'s return on equity of 67.52% beat Healthcare Services Group, Inc.'s return on equity of 11.82%.

DaVita, Inc. has a consensus price target of $151.71, signalling downside risk potential of -0.54%. On the other hand Healthcare Services Group, Inc. has an analysts' consensus of $23.50 which suggests that it could grow by 8%. Given that Healthcare Services Group, Inc. has higher upside potential than DaVita, Inc., analysts believe Healthcare Services Group, Inc. is more attractive than DaVita, Inc..

DaVita, Inc. has a beta of 0.994, which suggesting that the stock is 0.558% less volatile than S&P 500. In comparison Healthcare Services Group, Inc. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.446%.

DaVita, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healthcare Services Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita, Inc. pays -- of its earnings as a dividend. Healthcare Services Group, Inc. pays out -- of its earnings as a dividend.

DaVita, Inc. quarterly revenues are $3.6B, which are larger than Healthcare Services Group, Inc. quarterly revenues of $466.7M. DaVita, Inc.'s net income of $306M is higher than Healthcare Services Group, Inc.'s net income of $31.2M. Notably, DaVita, Inc.'s price-to-earnings ratio is 15.96x while Healthcare Services Group, Inc.'s PE ratio is 26.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita, Inc. is 0.85x versus 0.86x for Healthcare Services Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group, Inc. has a net margin of 8.45% compared to DaVita, Inc.'s net margin of 6.82%. DaVita, Inc.'s return on equity of 67.52% beat Pediatrix Medical Group, Inc.'s return on equity of 19.95%.

DaVita, Inc. has a consensus price target of $151.71, signalling downside risk potential of -0.54%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $21.33 which suggests that it could grow by 7.42%. Given that Pediatrix Medical Group, Inc. has higher upside potential than DaVita, Inc., analysts believe Pediatrix Medical Group, Inc. is more attractive than DaVita, Inc..

DaVita, Inc. has a beta of 0.994, which suggesting that the stock is 0.558% less volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.759, suggesting its less volatile than the S&P 500 by 24.082%.

DaVita, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita, Inc. pays -- of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend.

DaVita, Inc. quarterly revenues are $3.6B, which are larger than Pediatrix Medical Group, Inc. quarterly revenues of $493.8M. DaVita, Inc.'s net income of $306M is higher than Pediatrix Medical Group, Inc.'s net income of $33.7M. Notably, DaVita, Inc.'s price-to-earnings ratio is 15.96x while Pediatrix Medical Group, Inc.'s PE ratio is 10.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita, Inc. is 0.85x versus 0.88x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.